Preoperative predictors for early recurrence of resectable pancreatic cancer by unknown
RESEARCH Open Access
Preoperative predictors for early recurrence
of resectable pancreatic cancer
Kohei Nishio1, Kenjiro Kimura1*, Ryosuke Amano1, Sadaaki Yamazoe1, Go Ohrira1, Bunzo Nakata2,
Kosei Hirakawa1 and Masaichi Ohira1
Abstract
Background: The first-line treatment for resectable pancreatic cancer (RPC) is surgical resection. However, our
patients have often experienced early recurrence after curative resection for RPC, with desperately poor prognosis.
Some reports indicated that minimally distant metastasis not detected at operation might cause early recurrence.
The present study aimed to identify preoperative clinicopathological features of early recurrence after curative
resection of RPC.
Methods: Ninety RPC patients who underwent curative resection between 2000 and 2014 at our institution were
retrospectively analyzed.
Results: Of the 90 patients, 32 had recurrence within 1 year. Univariate analysis demonstrated that preoperative
serum carbohydrate antigen (CA19-9) ≥529 U/mL (P = 0.0011), preoperative serum s-pancreas-1 antigen (SPan-1)
≥37 U/mL (P = 0.0038), and histological grades G2–G4 (P = 0.0158) were significantly associated with recurrence
within 1 year after curative resection. Multivariate analysis demonstrated that preoperative serum CA19-9≥ 529 U/mL
(P = 0.0477) and histological grade G2–G4 (P = 0.0129) were independent predictors of recurrence within 1 year.
Recurrent cases within 1 year postoperatively had significantly more distant metastasis than cases with no recurrence
within 1 year (P < 0.001).
Conclusions: Preoperative serum CA19-9≥ 529 U/mL and histological grades G2–G4 were independent predictive
factors for recurrence within 1 year after pancreatectomy for RPC. Furthermore, recurrent cases within 1 year had more
frequent distant metastasis than cases with no recurrence within 1 year. These results suggest that RPC patients with
preoperative serum CA19-9≥ 529 U/mL should receive preoperative therapy rather than surgery.
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Background
Patients with pancreatic cancer have been reported to
have a 5-year overall survival (OS) of approximately 5%
[1]. Only 20% of patients with pancreatic cancer are
candidates for potentially radical resection [2]. Surgical
resection is associated with a median OS of 11 to
23 months and with a 5-year OS of about 20% [3, 4].
Furthermore, 60% of patients experience local and sys-
temic relapse within the first 12 months after curative
surgery [3]. Preoperative predictors of survival time
after surgery have been reported as tumor size [3],
preoperative lymph node metastasis [3], preoperative
serum carbohydrate antigen (CA19-9) level [2, 3, 5],
G3–G4 on pathological grading [2], duration of symptoms
[2], and preoperative modified Glasgow Prognostic Score
(mGPS) [6].
Moreover, some studies have suggested that minimally
distant metastasis undetectable even by recent advanced
diagnostic imaging might have existed at the time of sur-
gery in patients with early recurrence [7, 8]. In fact, oc-
cult peritoneal or liver metastatic disease has been
reported to be missed by CT in 4 to 15% of patients [3].
The National Comprehensive Cancer Network (NCCN)
guidelines recommend surgical resection as the first
choice for the treatment of RPC. However, some re-
searchers found that median OS of patients with RPC was
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approximately 12 months after surgery alone [9]. Other
researchers found that the median OS of patients with
RPC was <2 years after surgery and adjuvant therapy
[10, 11]. Furthermore, at least 25% of patients cannot
receive adjuvant chemotherapy because of complica-
tions related to surgery [9]. One group of investiga-
tors found that the median OS in patients undergoing
resection for RPC was 27 months using preoperative
chemoradiation therapy, while the median OS was
17 months in patients receiving surgery alone (P = 0.004)
[12]. However, no randomized controlled trials have been
reported on the efficacy of neoadjuvant chemotherapy for
RPC.
Although randomized controlled trials will give us the
answer whether preoperative therapy is needed for all
RPC, we think preoperative treatment is not needed for
all RPC. If early recurrence of RPC can be predicted be-
fore performing surgery, we suppose that preoperative
therapy should be selected prior to surgical resection for
RPC patients.
The aim of this study was to identify preoperative pre-
dictors of early recurrence after curative resection for
RPC. The results of this study could aid oncologists and
surgeons in discriminating high-risk cases of RPC in
which the cancer could recur within 1 year and selecting
the patients who would benefit from preoperative
therapy.
Methods
Study selection and inclusion and exclusion criteria
From January 2000 to December 2014, 183 patients
underwent pancreatic resection for pancreatic ductal
carcinoma at our institution. The study was approved by
the ethics committee of Osaka City University and was
in compliance with Helsinki declaration. Informed con-
sent was obtained from all patients to use specimens for
this study according to the institutional rules of our hos-
pital. All patients were histologically confirmed to have
the common type of invasive ductal carcinoma of the
pancreas double checked by two pathologists. Any pa-
tients with neuroendocrine carcinoma, mucinous cystic
carcinoma, or intraductal papillary mucinous carcinoma
were excluded. Of the 183 patients, 93 patients were ex-
cluded for the following reasons: cases with R2 resection
margins, 19; borderline resectable cancer, 52; unresect-
able cancer, 18; and censored cases, 4. The data from the
remaining 90 patients were retrospectively analyzed. All
of the 90 study patients were diagnosed with resectable
pancreatic cancer according to the NCCN guidelines,
version 2.2014.
Outcome measures
The demographic and clinical variables included age,
sex, body mass index (BMI), tumor location, tumor size,
histological grade, preoperative serum s-pancreas-1 anti-
gen (SPan-1) level, preoperative serum CA19-9 level,
preoperative serum carcinoembryonic antigen (CEA)
level, preoperative serum albumin, preoperative serum
white blood count (WBC), preoperative serum lympho-
cyte count, preoperative serum C-reactive protein (CRP),
and preoperative mGPS. In patients with preoperative
jaundice, the data after the jaundice was reduced was
used for the preoperative serum CA19-9 level. In pa-
tients with jaundice at our medical center, endoscopic or
percutaneous bile duct drainage is usually performed.
The CA19-9 level in all patients was the value after total
bilirubin was reduced to <5 mg/dL.
Surgery and pathology
Surgery involved standard or subtotal stomach-preserving
pancreaticoduodenectomy in 41 patients (45.6%), distal
pancreatectomy in 47 (52.2%), and total pancreatectomy
in two (2.2%). Regional lymph node dissection was per-
formed in all patients. The resected specimens were fixed
in 10% formalin at room temperature, and the size and
gross appearance of the tumor were recorded. The patho-
logic stage of all tumor specimens was determined using
the American Joint Committee on Cancer, 6th edition, sta-
ging system [13]. Tumor differentiation was classified ac-
cording to the World Health Organization (WHO)
classification as well differentiated (G1), moderately differ-
entiated (G2), poorly differentiated (G3), and undifferenti-
ated (G4) [14].
Adjuvant therapy and follow-up
All patients were followed for survival. Enhanced CT
was performed every 4 months within 1 year after the
surgery. One year later after the surgery, we performed
enhanced CT every 6 months. If it was necessary, we
added MRI or PET-CT. Basically before 2006, adjuvant
therapy has not been performed. As adjuvant chemo-
therapy, gemcitabine was administered by reference to
the results of CONKO-001 since 2006 [11]. S-1 was ad-
ministered by reference to the results of JASPAC01 since
2013 [15].
Statistical analysis
The clinicopathological features were compared between
patients who experienced recurrence within 1 year
(REC1) and those who did not (non-REC1). Categorical
variables were compared using the χ2 test or Fisher’s
exact test. A receiver operating characteristic (ROC)
curve was constructed to estimate the optimal cutoff
value of preoperative serum CA19-9 level, preoperative
serum SPan-1 level, tumor diameter, preoperative serum
CEA level, WBC, lymphocyte count, and CRP. The cut-
off value was determined as the point closest to the
upper left-hand corner of the graph. Variables with a
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significance of P < 0.05 on univariate analysis were in-
cluded in multivariate regression analysis to identify fac-
tors associated with recurrence within 1 year after
surgery. Survival was calculated using the Kaplan-Meier
method and compared between groups by the log-rank
test. P values <0.05 were considered significant. On mul-
tiple comparison test, Bonferroni correction was used.
Statistical analyses were performed using SAS version
9.0 software (SAS Institute, Inc., Cary, NC, USA).
Results
Characteristics of RPC patients
The characteristics of the 90 study patients who under-
went curative surgery for RPC are given in Table 1.
Among all the patients, 71 received adjuvant chemother-
apy. The median follow-up period was 26.8 (5.6–175.2)
months. The median OS was 41.5 months. The actuarial
3- and 5-year survival rates were 54.2 and 38.9%, re-
spectively. The median preoperative serum CA19-9
level of the 90 patients was 92 U/mL. A ROC curve
demonstrated that preoperative serum CA19-9 level
of 529 U/mL was the optimal cutoff point for recur-
rence within 1 year after surgery, with sensitivity of
86.2% and specificity of 50%. The area under the
curve (AUC) was 0.6815.
Univariate and multivariate analyses of recurrence within
1 year after surgery
Of the 90 patients, 32 (35.6%) experienced recurrence
within 1 year after surgery and 58 (64.4%) did not have
recurrence within 1 year. The median OS of REC1 was
14.2 months, compared to the survival not reaching the
median time in non-REC1, with a significant difference
between the groups (P < 0.0001).
Table 2 shows the results of univariate analysis of the
factors affecting REC1 among the 90 study patients. Sig-
nificant associations with REC1 were observed for histo-
logical grades G2–G4 (P = 0.0158), preoperative serum
SPan-1 level ≥35 U/mL (P = 0.0038), and preoperative
CA19-9 level ≥529 U/mL (P = 0.0011). Table 3 shows the
results of multivariate analysis of factors affecting REC1
for RPC. Histological grades G2–G4 (OR, 8.906; 95% CI,
1.493–172.463; P = 0.0129) and preoperative CA19-9
level ≥529 U/mL (OR, 3.130; 95% CI, 1.012-10.132;
P = 0.0477) were independent risk factors for REC1.
Figure 1 shows the survival curves of each independent
risk factor for REC1. The MST was 23.1 months in pa-
tients with CA19-9 ≥ 529 U/mL, compared to 55.9 months
in patients with CA19-9 < 529 U/mL, with a significant dif-
ference between the groups (P = 0.0038). The median OS
was 37.5 months in histological grade G2-G4, compared to
64.6 months in G1 (P = 0.0648). Figure 2 shows the
disease-free survival (DFS) of each independent risk factor
for REC1. Median DFS was 8.4 months in patients with
CA19-9 ≥ 529 U/mL, compared to 27.1 months in patients
with CA19-9 < 529 U/mL, with a significant difference be-
tween the groups (P = 0.0008). Median DFS was 16.1
months in patients with histological grade G2-G4, com-
pared to 51.5 months in patients with G1, with no
Table 1 Characteristics of patients with RPC
Characteristic Number
Age
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significant difference (P = 0.2197). In a further step, the 90
RPC patients were stratified into three groups: Group A,
CA19-9 < 37 U/mL; Group B, CA19-9 ≥ 37 U/mL and
<529 U/mL; Group C, CA19-9 ≥ 529 U/mL. We drew a
survival curve for each group, as shown in Fig. 3. The me-
dian OS in Group A did not reach the median time, the
median OS in Group B was 40.5 months, and the median
OS in Group C was 23.1 months. The survival times were
not statistically significantly different between the three
groups, but stratified Kaplan-Meier curves could be drawn
for these divided groups.
Recurrence patterns of RPC after surgery
Table 4 shows the comparison of postoperative recur-
rence of RPC. Among the 90 study patients, 60 (66.7%)
experienced recurrence. The median OS of the patients
with recurrence was 26.4 months, and their 5-year sur-
vival rate was 10%. Recurrence patterns were defined as
the first recurrent locations. Distant metastasis included
peritoneal dissemination, and local recurrence included
regional lymph node and plexus nerve recurrence. Pat-
terns of recurrence showed that 28 (46.7%) patients ini-
tially had distant metastasis and 32 (53.3%) patients
initially had local recurrence. Among REC1, 22 (68.8%)
patients had distant metastasis and 10 (31.2%) patients
had local recurrence. On the contrary, among non-REC1,
six (21.4%) patients had distant metastasis and 22 (78.6%)
patients had local recurrence. REC1 experienced signifi-
cantly more frequent distant metastasis than non-REC1.
Recurrence patterns and prognosis of the patients stratified
by preoperative serum CA19-9 level and tumor diameter
Next, we focused on tumor diameter and preoperative
serum CA19-9 level. We have encountered several patients
Table 2 Univariate analysis of factors affecting recurrence
within 1 year after curative pancreatectomy for RPC
Characteristics REC1 (n = 32)b Non-REC1 (n = 58)c P value
Age 0.6209
≥65 25 (78.1%) 42 (72.4%)
<65 7 (21.9%) 16 (27.6%)
Sex 0.3859
Male 17 (53.1%) 25 (43.1%)
Female 15 (46.9%) 33 (56.9%)
BMI 0.86
<17 3 (9.4%) 4 (6.9%)
18–25 24 (75%) 43 (74.1%)
>25 5 (15.6%) 11 (19%)
Location 0.27
Head 12 (37.5%) 30 (51.7%)
Body-tail 20 (62.5%) 28 (48.3%)
Tumor sizea 1
≥25 mm 19 (56.4%) 34 (58.6%)
<25 mm 13 (43.6%) 24 (41.4%)
Histological grade 0.0158
G2–G4 31 (96.9%) 45 (77.6%)
G1 1 (3.1%) 13 (22.4%)
Preoperative SPan-1a 0.0038
≥35 24 (75%) 24 (41.4%)
<35 8 (25%) 34 (58.6%)
Preoperative CA19-9a 0.0011
≥529 16 (50%) 9 (15.5%)
<529 16 (50%) 49 (84.5%)
Preoperative CEAa 0.1616
≥2.4 19 (56.4%) 43 (74.1%)
<2.4 13 (43.6%) 15 (25.9%)
Preoperative Alb 0.381
≥3.5 25 (78.1%) 50 (86.2%)
<3.5 7 (21.9%) 8 (13.8%)
Preoperative WBCa 0.1868
≥5400 19 (59.4%) 25 (43.1%)
<5400 13 (40.6%) 33 (56.9%)
Preoperative lymphocytea 0.3192
≥1023 26 (81.3%) 40 (69.0%)
<1023 6 (18.7%) 18 (31.0%)
Preoperative CRPa 0.7401
≥2.39 3 (9.4%) 8 (13.8%)
<2.39 29 (90.6%) 50 (86.2%)
mGPS 0.4168
1–2 8 (25%) 10 (17.2%)
0 24 (75%) 48 (82.8%)
Table 2 Univariate analysis of factors affecting recurrence
within 1 year after curative pancreatectomy for RPC (Continued)
Adjuvant therapy 0.4251
Yes 27 (84.4%) 44 (75.9%)
No 5 (15.6%) 14 (24.1%)
BMI body mass index, mGPS modified Glasgow prognostic score
aCutoff value of tumor size, SPan-1, CA19-9, CEA, WBC, lymphocyte, and CRP
was set by drawing ROC curve
bRecurrence within 1 year
cRecurrence at more than 1 year after surgery
Table 3 Multivariate analysis of factors affecting recurrence
within 1 year after curative pancreatectomy for RPC
Predictor OR 95% CI P value
Histological grade 8.906 1.493–172.463 0.0129
Preoperative CA19-9 3.13 1.012–10.132 0.0477
Preoperative SPan-1 2.811 0.939–8.746 0.0647
OR odds ratio, CI confidence interval
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in whom the preoperative serum CA19-9 level was very
high despite small tumor diameter without distant metasta-
sis; we suspect that such cases had distant metastasis
undetectable by preoperative imaging modalities. We
hypothesized that patients with small tumor diameter and
high preoperative serum CA19-9 level experienced recur-
rence in the form of distant metastasis more frequently
than the other patients. The study population was stratified
into four groups according to tumor diameter and pre-
operative CA19-9 as follows (Table 5): group 1 (n = 5),
CA19-9 level ≥529 U/mL and tumor size <25 mm;
group 2 (n = 32), CA19-9 level <529 U/mL and tumor
size <25 mm; group 3 (n = 20), CA19-9 level ≥529 U/
mL and tumor size ≥25 mm; and group 4 (n = 33),
CA19-9 level <529 U/mL and tumor size ≥25 mm. In
group 1, all patients had recurrence, and four of the five
patients (80%) experienced recurrence in the pattern of
distant metastasis. In group 2, 16 of the 32 patients (50%)
had recurrence, and seven of those 32 patients (21.9%) ex-
perienced recurrence in the pattern of distant metastasis.
In group 3, 16 of the 20 patients (80%) had recurrence,
and 11 of the 20 (55%) had distant metastasis. In group 4,
23 of the 33 patients (69.7%) had recurrence, and 10 of
the 23 (30.3%) had distant metastasis. Further, regarding
median OS, group 1 had a median OS of 12 months,
group 2 did not reach the median, group 3 had a median
OS of 27 months, and group 4 had a median OS of
45.3 months. The survival rate of group 1 was significantly
poorer than that of group 2 (P = 0.0002; significant values
of P < 0.01 was considered after Bonferroni correction).
a
b
Fig. 1 Survival curve of each independent risk factor. The median overall survival (OS) was 23.1 months in patients with CA19-9≥ 529 U/mL,
compared to 55.9 months in patients with CA19-9 < 529 U/mL, with a significant difference between the groups (P = 0.0038) (a). The median OS
was 37.5 months in patients with histological grades G2–G4, compared to 64.6 months in patients with G1, with no significant difference
(P = 0.0648) (b)
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Discussion
The present study indicated that the median OS of pa-
tients with RPC was 41.5 months, and 66.6% cases of pa-
tients with RPC experienced recurrence, including both
recurrence within 1 year and recurrence beyond 1 year
after surgery. The median OS of the recurrent cases
among the RPC patients was 26.4 months, and the 5-year
survival rate was 10%. Furthermore, the proportion of
cases having recurrence within 1 year after curative resec-
tion for RPC was 35.6%, and the median OS was
14.2 months. These results suggest that even if the pa-
tients with RPC could be treated by curative surgery, more
than half of them would experience recurrence, and their
prognosis would be poor. Furthermore, independent risk
factors for REC1 were histological grades G2–G4 and
preoperative serum CA19-9 ≥ 529 U/mL. REC1 experi-
enced recurrence in the pattern of more frequent distant
metastasis, which might suggest that occult metastasis
existed at the time of surgery. These results are crucial for
the treatment strategy of RPC in the future.
The present study identified preoperative CA19-9 level
≥529 U/mL and histological grade G2-G4 as preopera-
tive factors of recurrence within 1 year after curative re-
section for RPC. However, as it is usually difficult to
diagnose the histological grade before surgery, the de-
gree of differentiation is usually a post-resectional par-
ameter. In fact, at our institution, the histological grade
is not usually able to be diagnosed by endoscopic ultra-
sound (EUS)/fine needle aspiration (FNA) before sur-
gery. Therefore, histological type cannot be considered
a
b
Fig. 2 Disease-free survival of each independent risk factor. The median disease-free survival (DFS) was 8.4 months in patients with CA19-9≥ 529 U/mL,
compared to 27.1 months in patients with CA19-9 < 529 U/mL, with a significant difference between the groups (P= 0.0008) (a). The median DFS was
16.1 months in patients with histological grades G2-G4, compared to 51.5 months in patients with G1, with no significant difference (P = 0.2197) (b)
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as an appropriate preoperative factor. This suggests that
the most appropriate preoperative independent factor is
preoperative CA19-9 level ≥529 U/mL, excluding histo-
logical grade.
The CA19-9 tumor antigen was initially described by
Koprowski et al. as a colorectal cancer marker [16] and
is currently the most clinically useful marker of pancre-
atic cancer. Furthermore, CA19-9 is reliable as a possible
prognostic marker for tumor resectability, recurrence,
and survival [12, 17]. Berger et al. reported a longer me-
dian survival and greater percentage of patients surviv-
ing to 5 years among patients with either normal or
undetectable preoperative levels of CA19-9 compared
with patients having elevated levels [18]. Other investiga-
tors found that a postoperative decrease in CA19-9 and
a postoperative CA19-9 value <200 U/mL were both
significant predictors of survival in patients with pancre-
atic adenocarcinoma [4, 19]. Humphris et al. reported
that normalization of CA19-9 within 6 months of resec-
tion was a prognostic factor [20]. On the other hand, it
has been reported that only the preoperative CA19-9
level was associated with the prognosis or resectability
of patients. Nakao et al. reported that the only preopera-
tive predictor of survival time after surgery is a pre-
operative CA19-9 value ≥2000 U/mL [5]. Furthermore,
other investigators have found that elevated preoperative
CA19-9 levels were significantly associated with tumor
unresectability, although the reported cutoff levels
ranged from 100 to 350 U/mL [21–28]. In the present
study, the AUC of the cutoff point of the CA19-9 value
was 0.6815, and so it is difficult to say whether this AUC
is the optimal value. Henceforth, the optimal cutoff
value of CA19-9 should be evaluated by collecting a lar-
ger number of cases. Additionally, Turrini et al. sug-
gested that the preoperative serum CA19-9 level by itself
should not preclude surgery in patients who have under-
gone preoperative staging [29]. These investigators noted
that even patients with very high values of preoperative
CA19-9 may normalize their serum CA19-9 levels and
have an overall survival equivalent to patients with nor-
mal preoperative serum CA19-9 levels. In the current
study, we found that the group with higher CA 19-9
values tended to have poorer median OS. It is possible
that preoperative serum CA19-9 level is associated with
prognosis. But, careful evaluation is needed to determine
whether the prognosis of this patient group was based
on only the preoperative serum CA19-9 level.
We additionally examined the patterns of recurrence
of RPC. The patients who experienced recurrence within
Fig. 3 Survival curve of three groups stratified for preoperative serum CA19-9 level. The median OS in group A did not reach the median time,
the median OS in group B was 40.5 months, and the median OS in group C was 23.1 months. The survival times were not statistically significantly
different between the three groups, but stratified Kaplan-Meier curves could be drawn for these divided groups









Distant metastasis 28 (46.7%) 22 (68.8%) 6 (21.4%) <0.001
Liver 6 (10%) 5 (15.6%) 1 (3.6%)
Lung 7 (11.7%) 3 (9.4%) 4 (14.2%)
Dissemination 9 (15%) 8 (25%) 1 (3.6%)
Others 6 (10%) 6 (18.8%) 0 (0%)
Local recurrence 32 (53.3%) 10 (31.2%) 22 (78.6%) <0.001
Local 20 (33.3%) 6 (18.8%) 14 (50%)
Lymph node 5 (8.3%) 1 (3%) 4 (14.3%)
Plexus nerve 7 (11.7%) 3 (9.4%) 4 (14.3%)
aRecurrence within 1 year
bRecurrence at more than 1 year after surgery
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1 year had a greater amount of distant metastasis than
local recurrence. These results might suggest that pa-
tients with early recurrence after curative surgery had
minimally distant metastasis that was not detected via
imaging modalities at the time of surgery, and their le-
sions did not visibly appear until after surgery.
Furthermore, we examined the recurrence patterns of
each group stratified according to the combination of
preoperative serum CA19-9 level and tumor size. The
patients whose preoperative CA19-9 level was high des-
pite smaller tumor diameter tended to have the poorest
survival. From this result, it might also be speculated that
patients whose preoperative CA19-9 level was high
despite small tumor size had minimally distant metastasis
before or at the time of surgery. It should be kept in mind
that RPC patients with high preoperative serum CA19-9
levels have potentially distant metastasis. In particular, the
possibility exists that patients whose preoperative CA19-9
level is high despite smaller tumor diameter have distant
metastasis. Additionally, from the results of the present
study, an appropriate cutoff value of preoperative serum
CA19-9 value might be approximately 500 U/mL.
Chemotherapy for pancreatic cancer has recently been
developed. A previous study reported that the median OS
was 11.1 months after treatment with FOLFIRINOX for
metastatic pancreatic cancer [30] and was 8.5 months
after treatment with nab-paclitaxel plus gemcitabine [31].
The median OS of locally advanced pancreatic cancer is
24 months after first-line FOLFIRINOX with about 1/4
being resectable after this therapy [32]. Another study
found that neoadjuvant chemotherapy contributed to high
resection rates of local advanced pancreatic cancer [17].
Considering those reports, one option may be to adminis-
ter preoperative chemotherapy for RPC patients who have
high preoperative serum CA19-9 values, intending to ex-
clude those patients who have the potential for early re-
currence after surgery and to control minimally distant
metastasis in those patients. It has recently been reported
that staging laparoscopy in patients with local advanced
pancreatic ductal adenocarcinoma is effective for selecting
patients with occult distant organ metastasis [33]. To
perform staging laparoscope for RPC patients having high
preoperative CA19-9 values may make better patient
selection for preoperative therapy.
In this study, we mainly focused on preoperative ther-
apy. But, postoperative adjuvant therapy after curative
resection has been showed to improve survival [34].
CONKO-001 showed treatment with gemcitabine for
6 months after complete resection of pancreatic cancer
significant increased disease-free survival (DFS) and OS
compared with observation alone. ESPAC-3 showed no
significant difference in survival between adjuvant 5-
fluorouracil/folinic acid and adjuvant gemcitabine. But,
about 15% of patients may develop overt metastatic dis-
ease during postoperative recovery period; therefore,
early initiation of adjuvant chemotherapy within 20 days
after surgery has been shown to improve DFS and OS
[35, 36]. These reports may indicate we should perform
combination of preoperative therapy and postoperative
early adjuvant therapy for RPC cases with CA19-9 ≥ 529.
RCT trial (PREOPANC trial) as to preoperative radio-
chemotherapy versus immediate surgery for resectable
and borderline resectable pancreatic cancer is conducted
at the moment; the results will lead our studies to fur-
ther directions [37].
The limitations of the present study were as follows.
This was a retrospective study conducted at a single in-
stitution, and the sample size was small. Approximately
5–10% of the general population was Lewis antigen A-
and B-negative, which meant that they did not synthesize
CA19-9 antigen and would not have elevated levels, even
with pancreatic cancer. In the present series, the data
related to Lewis antigens A and B could not be included.
Conclusions
Preoperative serum CA19-9 level ≥529 U/mL and histo-
logical grades G2–G4 were independent predictive
factors for identifying recurrence within 1 year after
pancreatectomy for RPC. Furthermore, REC1 had more
frequent distant metastasis than non-REC1, which
suggested that patients experiencing recurrence within
1 year had minimally distant metastasis. This might indi-
cate the possibility that patients with high preoperative
serum CA19-9 values and have potential distant metas-
tasis despite suffering from RPC, especially, with small
tumor, should receive combination of preoperative ther-
apy and postoperative early therapy.
Table 5 Recurrent patterns and prognoses of patients stratified by preoperative serum CA19-9 level and tumor diameter











1 5 + − 5 (100%) 4 (80.0%) 1 (20%) 12
2 32 − − 16 (50%) 7 (21.9%) 9 (28.1%) Over 102.9 0.0002
3 20 + + 16 (80%) 11 (55%) 5 (25%) 27 0.0485
4 33 − + 23 (69.7%) 10 (30.3%) 13 (39.4%) 45.3 0.028
*Significant values of P < 0.01 was considered after Bonferroni correction
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Abbreviations
AUC: Area under the curve; BMI: Body mass index; BR-PC: Borderline
resectable pancreatic cancer; CA19-9: Carbohydrate antigen 19-9;
CEA: Carcinoembryonic antigen; CRP: C-reactive protein; DFS: Disease-free
survival; mGPS: Modified Glasgow Prognostic Score; MST: Median survival
time; NCCN: National Comprehensive Cancer Network; non-REC1: Patients
did not experience recurrence within 1 year after curative resection for RPC;
OS: Overall survival; OS: overall survival; REC1: Patients experienced
recurrence within 1 year after curative resection for RPC; ROC: Receiver
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